The Stock Wall Street Mispriced in Healthcare

Analyst Targets

• Barclays — Raised price target to $20.00 (Equal-Weight)
• KeyBanc — Raised price target to $20.00 (Overweight)
• Telsey Advisory Group — Lowered price target to $16.00 (Market Perform)
• BTIG — Price target $15.00 (Buy)
• Consensus (9 analysts, S&P Global) — Average target $17.63; range $14 to $22

At Friday’s close of $14.26, FIGS sits at the low end of the analyst target range. That positioning matters. It means the re-rating the stock received on earnings day has already consumed most of the consensus upside, and further appreciation depends on the company proving its second-half performance independently of the tailwinds that inflated Q2.

The Investment Thesis

One of the most underpenetrated uniform markets in America is not industrial workwear or food service. It is healthcare apparel, and the company that has built the dominant brand within it just delivered three consecutive quarters of 25%-plus revenue growth while simultaneously navigating a supply chain disruption and a one-time $20.5 million tariff refund that complicates everything a forward-looking investor needs to underwrite.

That is the FIGS situation as of August 10, 2026. The quarter was genuinely strong. The stock deserved to move. The harder question, the one worth spending time on, is whether the re-rating overshot or whether the market is still underestimating what FIGS can become once the noise clears.

After conducting a full market scan this week, no other consumer company offered a more compelling combination of structural growth tailwind, identifiable execution edge, and a valuation debate with a clear, near-term resolution date: Q3 earnings. That asymmetry earned FIGS this issue.

The Market Opportunity

Healthcare and social assistance is projected to be the fastest growing U.S. industry sector from 2024 to 2034. The driver is demographic: an aging population requiring more care from a workforce that is itself expanding to meet demand. That workforce wears uniforms every day of their working lives. Replenishment is not optional, and price sensitivity is lower than in almost any other apparel category because the purchase is professional, not discretionary.

The global medical scrubs market was estimated at $54.27 billion in 2025 and is forecast to reach $73.1 billion by 2030. FIGS currently holds less than 1% global market share. That number is not a warning sign. It is the entire investment case, expressed in a single figure.

What changed in 2026 is that FIGS started proving it can grow into that market at scale, with improving unit economics, without degrading brand perception. Three quarters of 25%-plus growth is the evidence. The debate is no longer about whether the business model works. It is about how much of the future is already priced in at $14.

Why FIGS Is the Best Way to Participate

FIGS sells premium scrubwear and adjacent healthcare apparel direct-to-consumer through its website, mobile app, and a growing physical retail footprint called Community Hubs. The direct model matters because it preserves margin, controls brand presentation, and generates first-party customer data that competitors selling through distributors and hospital supply chains cannot replicate.

No other publicly traded company is pursuing this market with FIGS’s brand positioning, customer loyalty metrics, or data infrastructure. Generic scrub brands compete on price. FIGS competes on identity, which is why its customers spend more per visit as the relationship ages rather than less.

The Community Hub retail expansion adds a layer most analysts have not fully valued. Roughly 40% of Hub visitors are new to the brand, meaning physical locations are functioning as customer acquisition infrastructure rather than simply serving existing fans. For a company built entirely on digital, that efficiency from physical retail changes the long-term customer acquisition cost trajectory in a way the current P/E does not reflect.

The Numbers

FIGS reported Q2 2026 results on August 6. The beat was not incremental.

• Revenue: $196.6M vs. $186.1M estimate (+$10.5M beat)
• Adjusted EPS: $0.15 vs. $0.07 estimate (more than 2x the consensus)
• Net revenue growth: 28.8% year over year
• Gross margin: 75.2% (+820 basis points year over year)
• Active customers: 3.1M (+13.2% year over year)
• Average order value: $127 (company record, +8.5%)
• Net revenues per active customer: $229 (+10.1%, company record)
• Scrubwear revenue: $161.2M (+26.5%)
• Non-scrubwear revenue: $35.4M (+40.3%)
• Free cash flow (H1 2026): $38.6M vs. negative $5.6M in H1 2025
• Share repurchases (Q2): ~$24M at a weighted average of $11.94/share
• Total repurchase authorization: $200M (board raised by $100M on August 6)

The guidance revision was equally aggressive. FIGS raised its full-year 2026 revenue growth outlook to approximately 20%, from a prior range of 14% to 16%. Operating margin guidance moved to approximately 10.8% from 7.8% to 8.0%. Adjusted EBITDA margin guidance was raised to 14.8% to 15.0% from 13% to 13.2%. All of this happened while management was actively managing a supply chain disruption, which is the detail that most separates a genuine fundamental re-rating from a short-squeeze move on good optics.

Competitive Advantage

FIGS’s moat is built on brand, data, and product architecture. The brand speaks directly to the identity of healthcare professionals, not just their need for functional workwear. That emotional positioning produces loyalty statistics that traditional apparel companies cannot match: customers returning more frequently, spending more per order, and trading up into higher-margin product categories as the relationship deepens.

The product architecture is expanding deliberately. FORMx fabric penetration nearly doubled year over year. The FIBREx line is being positioned for the second half of 2026. The August 2026 acquisition of V Coterie, a maker of medical-themed jewelry, pins, and charms, extends the brand into accessories and deepens the emotional connection with the healthcare community. V Coterie’s founder joined FIGS as part of the transaction. Management characterized the deal as financially immaterial but strategically meaningful as a wallet-share and brand-depth initiative.

The TEAMS platform, FIGS’s B2B offering for hospitals and health systems, is transitioning from pilot to core revenue driver. Institutional sales add a procurement channel that is entirely different from DTC, with longer contract cycles and predictable reorder patterns. It is also the channel most insulated from single-supplier risk because institutional buyers plan further in advance.

Internationally, FIGS now operates in 85 markets. The international revenue growth rate has been running well above the company average, reflecting brand demand in markets where FIGS has only just begun to invest in awareness. That geographic optionality is not in the current valuation.

Risks: The Strongest Opposing Arguments

The $20.5 million IEEPA tariff refund is the central risk to every forward margin estimate derived from Q2 results. FIGS recognized a $15.4 million reduction to cost of goods sold and a $5.1 million inventory adjustment from duties that were previously expensed and are now recoverable following the Supreme Court’s February 2026 ruling on IEEPA tariffs. That refund flows directly through gross margin. Strip it out and the 820 basis point year-over-year expansion looks dramatically different. FIGS CFO Sarah Oughtred acknowledged on the Q2 earnings call that the 15% EBITDA margin guidance includes the tariff refund benefit and described it as a factor investors need to consider when thinking about 2027.

The Jordan WRO is the second structural risk. On June 23, 2026, CBP issued a Withhold Release Order against Jordanian garment manufacturers citing forced labor concerns. One of FIGS’s Jordan-based suppliers was covered, and that supplier produced approximately one-third of Q2 finished goods. FIGS is rerouting production and plans to absorb some costs through air freight, but Q3 inventory is expected to remain down double digits year over year as supplier transitions continue. Management says it can still support its raised revenue targets. The market will find out in November.

Three risks compound simultaneously heading into Q3 and Q4. New U.S. import tariffs on certain sourcing routes are increasing product costs. Non-scrubwear, growing at 40.3% and now representing 18% of revenue, carries lower margins than scrubwear, so the revenue mix shift that is broadening FIGS’s product reach is also creating a structural gross margin headwind. And the Q4 revenue growth guide decelerates to approximately 10%, roughly half the Q2 and Q3 pace. That deceleration is by management’s own admission. If it arrives alongside any supply friction or inventory shortfall, the re-rating could reverse quickly.

On valuation, FIGS trades at approximately 47x forward earnings. That is roughly double the broad apparel peer average. At $14.26, the stock is at the low end of the post-earnings analyst target range, which means most of the near-term upside identified by the sell side is already accounted for in Friday’s close.

What to Watch

• Q3 gross margin, ex-tariff items: This is the single most important data point. If underlying gross margin holds above 68% without refund tailwinds, the bull case is intact. If it prints below 65%, the margin story is in question.
• Inventory levels and product availability: Management guided to double-digit year-over-year inventory declines through Q3 due to the Jordan transition. Any revenue miss tied to inventory shortfalls would confirm the WRO risk is larger than guided.
• Non-scrubwear margin trajectory: Non-scrubwear is growing fast but carrying lower margins. Watch whether management takes pricing action or improves mix within the category to stabilize blended gross margin.
• Q4 deceleration confirmation: The guide implies approximately 10% revenue growth in Q4, a sharp step-down. Monitor whether analysts revise Q4 estimates down further once Q3 results land.
• International growth rate: The international business has been running at nearly 50% year-over-year growth. Any deceleration there removes an important valuation argument about long-term runway.
• TEAMS platform traction: Institutional sales are transitioning from pilot to core. Any measurable acceleration in the B2B channel would be a meaningful positive surprise given its predictable, recurring nature.

Forward Scenarios

• Bull: Underlying gross margin holds above 68% in Q3 and Q4 without tariff refund support. Jordan supply disruption proves manageable, inventory recovers by year-end, and Q4 revenue growth comes in above the 10% guide. International accelerates. TEAMS adds a meaningful institutional revenue line by year-end. The stock re-rates toward the $20 target held by Barclays and KeyBanc.
• Base: Q3 gross margin compresses to the 66% to 68% range as the tariff refund disappears and air freight costs flow through. Revenue meets the raised guide. Jordan disruption creates some inventory friction but does not derail growth. Q4 delivers approximately 10% growth as guided. Stock consolidates in the $13 to $16 range as investors await 2027 visibility.
• Bear: Q3 gross margin prints below 65%. Jordan disruption proves deeper than communicated, and inventory shortfalls drive a Q3 revenue miss. Non-scrubwear margin dilution compounds. The market concludes that the Q2 beat was disproportionately driven by the $20.5 million tariff refund, and the stock retraces toward the $10 to $12 range as the 47x multiple compresses toward peer averages.

Technical Overlay

FIGS closed Friday at $14.26 after gapping from approximately $11.25 pre-earnings. The gap zone between $11.25 and $12.50 represents the first meaningful support level if the stock gives back ground. The 52-week range runs from $6.07 to $17.48, meaning Friday’s close sits roughly in the middle of the full-year range but well below the high reached earlier in 2026. Prior resistance around $15 to $16 is now the first test. Breaking and holding above $16 would open a path toward the $18 to $20 analyst targets. A close back below $12.50 would suggest the earnings gap is filling and the fundamental debate is shifting bearish heading into Q3.

Bottom Line

The debate about FIGS is not whether the business is good. Three consecutive quarters above 25% revenue growth, a record average order value, improving free cash flow, and a guidance raise delivered mid-supply-disruption: that is a business performing well. The debate is about what is real and what is temporary.

The $20.5 million tariff refund will not recur. The Jordan supplier disruption is not fully resolved. New sourcing tariffs are an ongoing cost headwind with no recovery mechanism. And a stock trading at 47x forward earnings in a tariff-disrupted supply chain environment has very little margin for error.

What ultimately determines whether FIGS is worth owning at $14 is a single question: can this business sustain gross margins above 68% in a normalized environment, without one-time refunds and without supply chain disruptions? If yes, the long-term thesis holds and the current valuation is defensible given the growth rate. If no, the re-rating overshot and the second half of 2026 will correct it.

Q3 earnings answer that question. Watch closely.

For informational purposes only.